New insights in bilirubin metabolism and their clinical implications

World Journal of Gastroenterology

Volumn 19, Issue 38, 2013, Pages 6398-6407

  Sticova, Eva ^a   Jirsa, Milan ^a,b  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

ABCC2; Hereditary jaundice; Hyperbilirubinemia; Organic anion transporting polypeptide 1B1; Organic anion transporting polypeptide 1B3; UGT1A1

Indexed keywords

BILIRUBIN GLUCURONIDE; COPROPORPHYRIN; GLUCURONOSYLTRANSFERASE 1A1; MULTIDRUG RESISTANCE PROTEIN 2; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; UNCLASSIFIED DRUG;

AUTOSOMAL RECESSIVE DISORDER; BILIRUBIN METABOLISM; CHOLESTASIS; CRIGLER NAJJAR SYNDROME; DUBIN JOHNSON SYNDROME; GENE MUTATION; GILBERT DISEASE; GLUCURONIDATION; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; KERNICTERUS; LIVER CELL; LIVER CLEARANCE; MOLECULAR GENETICS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; ROTOR SYNDROME;

ABCC2; HEREDITARY JAUNDICE; HYPERBILIRUBINEMIA; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B1; ORGANIC ANION TRANSPORTING POLYPEPTIDE 1B3; UGT1A1;

ANIMALS; BILIRUBIN; BIOLOGICAL MARKERS; CHOLESTASIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERBILIRUBINEMIA, HEREDITARY; JAUNDICE; LIVER; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; PHENOTYPE; RISK FACTORS;

EID: 84885600167     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i38.6398     Document Type: Review

References (143)

1. Stadeler G. Uber die Farbstoffe der Galle. Anaalen d Chemie u Pharmacie 1864; 132: 323-354
2. London IM, West R, Shemin D, Rittenberg D. On the origin of bile pigment in normal man. J Biol Chem 1950; 184: 351-358 [PMID: 15422003]
3. Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies of bilirubin kinetics in normal adults. J Clin Invest 1969; 48: 2176-2190 [PMID: 5824077 DOI: 10.1172/JCI106184]
4. Tenhunen R, Marver HS, Schmid R. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proc Natl Acad Sci USA 1968; 61: 748-755 [PMID: 4386763]
5. Schmid R. The identification of direct-reacting bilirubin as bilirubin glucuronide. J Biol Chem 1957; 229: 881-888 [PMID: 13502349]
6. Schmid R. Direct-reacting bilirubin, bilirubin glucuronide, in serum, bile and urine. Science 1956; 124: 76-77 [PMID: 13337353 DOI: 10.1126/science.124.3211.76]
7. Gorski JP, Kasper CB. Purification and properties of microsomal UDP-glucuronosyltransferase from rat liver. J Biol Chem 1977; 252: 1336-1343 [PMID: 402364]
8. Burchell B. Purification of UDP-glucuronyltransferase from untreated rat liver. FEBS Lett 1977; 78: 101-104 [PMID: 406146 DOI: 10.1016/0014-5793(77)80283-4]
9. Fisher MB, Paine MF, Strelevitz TJ, Wrighton SA. The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 2001; 33: 273-297 [PMID: 11768770 DOI: 10.1081/DMR-120000653]
10. Kokudo N, Takahashi S, Sugitani K, Okazaki T, Nozawa M. Supplement of liver enzyme by intestinal and kidney transplants in congenitally enzyme-deficient rat. Microsurgery 1999; 19: 103-107 [PMID: 10188835]
11. Owens IS, Basu NK, Banerjee R. UDP-glucuronosyltransferases: gene structures of UGT1 and UGT2 families. Methods Enzymol 2005; 400: 1-22 [PMID: 16399340 DOI: 10.1016/ S0076-6879(05)00001-7]
12. Burchell B. Identification and purification of mutiple forms of UDP-glucuronosyltransferase. Rev Biochem Toxicol 1981; 3: 1
13. Roy Chowdhury J, Roy Chowdhury N, Falany CN, Tephly TR, Arias IM. Isolation and characterization of multiple forms of rat liver UDP-glucuronate glucuronosyltransferase. Biochem J 1986; 233: 827-837 [PMID: 3085655]
14. Burchell B, Brierley CH, Monaghan G, Clarke DJ. The structure and function of the UDP-glucuronosyltransferase gene family. Adv Pharmacol 1998; 42: 335-338 [PMID: 9327909 DOI: 10.1016/S1054-3589(08)60758-9]
15. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 2000; 40: 581-616 [PMID: 10836148 DOI: 10.1146/annurev.pharmtox.40.1.581]
16. Cherrington NJ, Hartley DP, Li N, Johnson DR, Klaassen CD. Organ distribution of multidrug resistance proteins 1, 2, and 3 (Mrp1, 2, and 3) mRNA and hepatic induction of Mrp3 by constitutive androstane receptor activators in rats. J Pharmacol Exp Ther 2002; 300: 97-104 [PMID: 11752103]
17. Gartung C, Matern S. Molecular regulation of sinusoidal liver bile acid transporters during cholestasis. Yale J Biol Med 1997; 70: 355-363 [PMID: 9626756]
18. van de Steeg E, Wagenaar E, van der Kruijssen CM, Burggraaff JE, de Waart DR, Elferink RP, Kenworthy KE, Schinkel AH. Organic anion transporting polypeptide 1a/1b-knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. J Clin Invest 2010; 120: 2942-2952 [PMID: 20644253 DOI: 10.1172/JCI42168]
19. Iusuf D, van de Steeg E, Schinkel AH. Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends Pharmacol Sci 2012; 33: 100-108 [PMID: 22130008 DOI: 10.1016/j.tips.2011.10.005]
20. König J, Cui Y, Nies AT, Keppler D. Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J Biol Chem 2000; 275: 23161-23168 [PMID: 10779507 DOI: 10.1074/jbc.M001448200]
21. König J, Cui Y, Nies AT, Keppler D. A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am J Physiol Gastrointest Liver Physiol 2000; 278: G156-G164 [PMID: 10644574]
22. Iusuf D, van de Steeg E, Schinkel AH. Hepatocyte hopping of OATP1B substrates contributes to efficient hepatic detoxification. Clin Pharmacol Ther 2012; 92: 559-562 [PMID: 23010652 DOI: 10.1038/clpt.2012.143]
23. Zhang W, He YJ, Gan Z, Fan L, Li Q, Wang A, Liu ZQ, Deng S, Huang YF, Xu LY, Zhou HH. OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin Exp Pharmacol Physiol 2007; 34: 1240-1244 [PMID: 17973861]
24. Sanna S, Busonero F, Maschio A, McArdle PF, Usala G, Dei M, Lai S, Mulas A, Piras MG, Perseu L, Masala M, Marongiu M, Crisponi L, Naitza S, Galanello R, Abecasis GR, Shuldiner AR, Schlessinger D, Cao A, Uda M. Common variants in the SLCO1B3 locus are associated with bilirubin levels and unconjugated hyperbilirubinemia. Hum Mol Genet 2009; 18: 2711-2718 [PMID: 19419973 DOI: 10.1093/hmg/ddp203]
25. Briz O, Serrano MA, MacIas RI, Gonzalez-Gallego J, Marin JJ. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placentamaternal liver tandem excretory pathway for foetal bilirubin. Biochem J 2003; 371: 897-905 [PMID: 12568656]
26. Macias RI, Marin JJ, Serrano MA. Excretion of biliary compounds during intrauterine life. World J Gastroenterol 2009; 15: 817-828 [PMID: 19230042 DOI: 10.3748/wjg.15.817]
27. Stocker R, Yamamoto Y, McDonagh AF, Glazer AN, Ames BN. Bilirubin is an antioxidant of possible physiological importance. Science 1987; 235: 1043-1046 [PMID: 3029864 DOI: 10.1126/science.3029864]
28. Dennery PA, McDonagh AF, Spitz DR, Rodgers PA, Stevenson DK. Hyperbilirubinemia results in reduced oxidative injury in neonatal Gunn rats exposed to hyperoxia. Free Radic Biol Med 1995; 19: 395-404 [PMID: 7590389 DOI: 10.1016/089 1-5849(95)00032-S]
29. Mayer M. Association of serum bilirubin concentration with risk of coronary artery disease. Clin Chem 2000; 46: 1723-1727 [PMID: 11067805]
30. Ollinger R, Kogler P, Troppmair J, Hermann M, Wurm M, Drasche A, Königsrainer I, Amberger A, Weiss H, Ofner D, Bach FH, Margreiter R. Bilirubin inhibits tumor cell growth via activation of ERK. Cell Cycle 2007; 6: 3078-3085 [PMID: 18073533 DOI: 10.4161/cc.6.24.5022]
31. Lacko M, Roelofs HM, Te Morsche RH, Voogd AC, Ophuis MB, Peters WH, Manni JJ. Genetic polymorphism in the conjugating enzyme UGT1A1 and the risk of head and neck cancer. Int J Cancer 2010; 127: 2815-2821 [PMID: 21351260 DOI: 10.1002/ijc.25296]
32. Horsfall LJ, Rait G, Walters K, Swallow DM, Pereira SP, Nazareth I, Petersen I. Serum bilirubin and risk of respiratory disease and death. JAMA 2011; 305: 691-697 [PMID: 21325185]
33. Keshavan P, Schwemberger SJ, Smith DL, Babcock GF, Zucker SD. Unconjugated bilirubin induces apoptosis in colon cancer cells by triggering mitochondrial depolarization. Int J Cancer 2004; 112: 433-445 [PMID: 15382069 DOI: 10.1002/ ijc.20418]
34. Hervieux J. De l'ictere des nouveau-nes. Paris: These Med, 1847
35. Schmorl G. Zur Kenntnis des ikterus neonatatorum, inbesondere der dabei auftreten den gehirnveranderungen. Verh Dtsch Ges Pathol 1903; 6: 109
36. Schiff D, Chan G, Poznansky MJ. Bilirubin toxicity in neural cell lines N115 and NBR10A. Pediatr Res 1985; 19: 908-911 [PMID: 4047759]
37. Mustafa MG, Cowger ML, King TE. Effects of bilirubin on mitochondrial reactions. J Biol Chem 1969; 244: 6403-6414 [PMID: 4982202]
38. Diamond I, Schmid R. Oxidative phosphorylation in experimental bilirubin encephalopathy. Science 1967; 155: 1288-1289 [PMID: 6018655]
39. Strumia E. [Effect of bilirubin on some hydrolases]. Boll Soc Ital Biol Sper 1959; 35: 2160-2162 [PMID: 13835320]
40. Flitman R, Worth MH. Inhibition of hepatic alcohol dehydrogenase by bilirubin. J Biol Chem 1966; 241: 669-672 [PMID: 5908133]
41. Katoh R, Kashiwamata S, Niwa F. Studies on cellular toxicity of bilirubin: Effect on the carbohydrate metabolism in the young rat brain. Brain Res 1975; 83: 81-92 [DOI: 10.1016/0006-8993(75)90860-4]
42. Greenfield S, Majumdar AP. Bilirubin encephalopathy: effect on protein synthesis in the brain of the Gunn rat. J Neurol Sci 1974; 22: 83-89 [PMID: 4857425]
43. Majumdar AP. Bilirubin encephalopathy: effect on RNA polymerase activity and chromatin template activity in the brain of the Gunn rat. Neurobiology 1974; 4: 425-431 [PMID: 4453356]
44. Geier A, Dietrich CG, Voigt S, Kim SK, Gerloff T, Kullak-Ublick GA, Lorenzen J, Matern S, Gartung C. Effects of proinflammatory cytokines on rat organic anion transporters during toxic liver injury and cholestasis. Hepatology 2003; 38: 345-354 [PMID: 12883478 DOI: 10.1053/jhep.2003.50317]
45. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773: 283-308 [PMID: 17291602 DOI: 10.1016/ j.bbamcr.2006.04.014]
46. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007; 24: 1803-1823 [PMID: 17404808 DOI: 10.1007/ s11095-007-9289-1]
47. Thompson R, Jansen PL. Genetic defects in hepatocanalicular transport. Semin Liver Dis 2000; 20: 365-372 [PMID: 11076402 DOI: 10.1055/s-2000-9384]
48. Lee J, Boyer JL. Molecular alterations in hepatocyte transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 2000; 20: 373-384 [PMID: 11076403 DOI: 10.1055/ s-2000-9390]
49. Gunn CH. Hereditary acholuric jaundice in a new mutant strain of rats. J Hered 1938; 29: 137-139
50. Roy Chowdhury J, Van ES HHG, Roy Chowdhury N. Gunn rat: An animal model of deficiency of bilirubin conjugation. In: Tavoloni N, Berk PD, editors. Hepatic Transport and Bile Secretion: Physiology and Pathophysiology. New York: Raven Press, 1992: 713
51. Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner MJ, Hardiman G, Bélanger A, Tukey RH. Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem 2008; 283: 7901-7911 [PMID: 18180294 DOI: 10.1074/jbc.M709244200]
52. Portman OW, Roy Chowdhury J, Roy Chowdhury N, Alexander M, Cornelius CE, Arias IM. A nonhuman primate model of Gilbert's syndrome. Hepatology 1984; 4: 175-179 [PMID: 6706295 DOI: 10.1002/hep.1840040202]
53. Portman OW, Alexander M, Cornelius CE, Chowdhury JR, Chowdhury NR, Arias IM. The effects of nutrition on unconjugated plasma bilirubin concentrations in squirrel monkeys. Hepatology 1984; 4: 454-460 [PMID: 6724513 DOI: 10.1002/ hep.1840040318]
54. Jansen PL, van Klinken JW, van Gelder M, Ottenhoff R, Elferink RP. Preserved organic anion transport in mutant TRrats with a hepatobiliary secretion defect. Am J Physiol 1993; 265: G445-G452 [PMID: 8214066]
55. Kawaguchi A, Nozaki Y, Hosokawa S, Tagaya O, Mikami T, Wakabayashi T. [Establishment of hyperbilirubinuria rat mutant--a new animal model for jaundice]. Jikken Dobutsu 1994; 43: 37-44 [PMID: 8119341]
56. Yamazaki K, Mikami T, Hosokawa S, Tagaya O, Nozaki Y, Kawaguchi A, Funami H, Katoh H, Yamamoto N, Wakabayashi T. A new mutant rat with hyperbilirubinuria (hyb). J Hered 1995; 86: 314-317 [PMID: 7658001]
57. Cornelius CE, Arias IM, Osburn BI. Hepatic pigmentation with photosensitivity: A Syndrome in corriedale sheep resembling dubin-johnson syndrome in man. J Am Vet Med Assoc 1965; 146: 709-713 [PMID: 14317604]
58. Chu XY, Strauss JR, Mariano MA, Li J, Newton DJ, Cai X, Wang RW, Yabut J, Hartley DP, Evans DC, Evers R. Characterization of mice lacking the multidrug resistance protein MRP2 (ABCC2). J Pharmacol Exp Ther 2006; 317: 579-589 [PMID: 16421286 DOI: 10.1124/jpet.105.098665]
59. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, Mori M, Kakizaki S, Sueyoshi T, Negishi M, Miwa M. Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 2002; 292: 492-497 [PMID: 11906189 DOI: 10.1006/ bbrc.2002.6683]
60. Sugatani J, Kojima H, Ueda A, Kakizaki S, Yoshinari K, Gong QH, Owens IS, Negishi M, Sueyoshi T. The phenobarbital response enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CA-R. Hepatology 2001; 33: 1232-1238 [PMID: 11343253 DOI: 10.1053/jhep.2001.24172]
61. Crigler JF, Najjar VA. Congenital familial nonhemolytic jaundice with kernicterus. Pediatrics 1952; 10: 169-180 [PMID: 12983120]
62. Ritter JK, Yeatman MT, Ferreira P, Owens IS. Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient. J Clin Invest 1992; 90: 150-155 [PMID: 1634606 DOI: 10.1172/JCI115829]
63. Jansen PL. Diagnosis and management of Crigler-Najjar syndrome. Eur J Pediatr 1999; 158 Suppl 2: S89-S94 [PMID: 10603107 DOI: 10.1007/PL00014330]
64. Karon M, Imach D, Schwartz A. Effective phototherapy in congenital nonobstructive, nonhemolytic jaundice. N Engl J Med 1970; 282: 377-380 [PMID: 5411133 DOI: 10.1056/ NEJM197002122820709]
65. Shevell MI, Bernard B, Adelson JW, Doody DP, Laberge JM, Guttman FM. Crigler-Najjar syndrome type I: treatment by home phototherapy followed by orthotopic hepatic transplantation. J Pediatr 1987; 110: 429-431 [PMID: 3546653 DOI: 10.1016/S0022-3476(87)80510-3]
66. Fox IJ, Chowdhury JR, Kaufman SS, Goertzen TC, Chowdhury NR, Warkentin PI, Dorko K, Sauter BV, Strom SC. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422-1426 [PMID: 9580649 DOI: 10.1056/NEJM199805143382004]
67. Matas AJ, Sutherland DE, Steffes MW, Mauer SM, Sowe A, Simmons RL, Najarian JS. Hepatocellular transplantation for metabolic deficiencies: decrease of plasms bilirubin in Gunn rats. Science 1976; 192: 892-894 [PMID: 818706 DOI: 10.1126/ science.818706]
68. Ilan Y, Attavar P, Takahashi M, Davidson A, Horwitz MS, Guida J, Chowdhury NR, Chowdhury JR. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest 1996; 98: 2640-2647 [PMID: 8958229 DOI: 10.1172/JCI119085]
69. Takahashi M, Ilan Y, Chowdhury NR, Guida J, Horwitz M, Chowdhury JR. Long term correction of bilirubin-UDPglucuronosyltransferase deficiency in Gunn rats by administration of a recombinant adenovirus during the neonatal period. J Biol Chem 1996; 271: 26536-26542 [PMID: 8900123 DOI: 10.1074/jbc.271.43.26536]
70. Arias IM. Chronic unconjugated hyperbilirubinemia without overt signs of hemolysis in adolescents and adults. J Clin Invest 1962; 41: 2233-2245 [PMID: 14013759 DOI: 10.1172/ JCI104682]
71. Gollan JL, Huang SN, Billing B, Sherlock S. Prolonged survival in three brothers with severe type 2 Crigler-Najjar syndrome. Ultrastructural and metabolic studies. Gastroenterology 1975; 68: 1543-1555 [PMID: 805737]
72. Moghrabi N, Clarke DJ, Boxer M, Burchell B. Identification of an A-to-G missense mutation in exon 2 of the UGT1 gene complex that causes Crigler-Najjar syndrome type 2. Genomics 1993; 18: 171-173 [PMID: 8276413 DOI: 10.1006/ geno.1993.1451]
73. Hunter JO, Thompson RP, Dunn PM, Williams R. Inheritance of type 2 Crigler-Najjar hyperbilirubinaemia. Gut 1973; 14: 46-49 [PMID: 4692254]
74. Labrune P, Myara A, Hennion C, Gout JP, Trivin F, Odievre M. Crigler-Najjar type II disease inheritance: a family study. J Inherit Metab Dis 1989; 12: 302-306 [PMID: 2515370 DOI: 10.1007/BF01799221]
75. Seppen J, Bosma PJ, Goldhoorn BG, Bakker CT, Chowdhury JR, Chowdhury NR, Jansen PL, Oude Elferink RP. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest 1994; 94: 2385-2391 [PMID: 7989595 DOI: 10.1172/JCI117604]
76. Gilbert A, Lereboullet P. La cholemie simple familiale. Semaine Medicale 1901; 21: 241-243
77. Nixon JC, Monahan GJ. Gilbert's disease and the bilirubin tolerance test. Can Med Assoc J 1967; 96: 370-373 [PMID: 6017546]
78. Schmid R. Gilbert's syndrome--a legitimate genetic anomaly? N Engl J Med 1995; 333: 1217-1218 [PMID: 7565981 DOI: 10.1056/NEJM199511023331812]
79. Thomsen HF, Hardt F, Juhl E. Diagnosis of Gilbert's syndrome. Reliability of the caloric restriction and phenobarbital stimulation tests. Scand J Gastroenterol 1981; 16: 699-703 [PMID: 7323703]
80. Barth RF, Grimley PM, Berk PD, Bloomer JR, Howe RB. Excess lipofuscin accumulation in constitutional hepatic dysfunction (Gilbert's syndrome). Light and electron microscopic observations. Arch Pathol 1971; 91: 41-47 [PMID: 5538621]
81. Dawson J, Seymour CA, Peters TJ. Gilbert's syndrome: analytical subcellular fractionation of liver biopsy specimens. Enzyme activities, organelle pathology and evidence for subpopulations of the syndrome. Clin Sci (Lond) 1979; 57: 491-497 [PMID: 391473 DOI: 10.1042/cs0570491]
82. Black M, Billing BH. Hepatic bilirubin udp-glucuronyl transferase activity in liver disease and gilbert's syndrome. N Engl J Med 1969; 280: 1266-1271 [PMID: 5770050 DOI: 10.1056/NEJM196906052802303]
83. Owens D, Evans J. Population studies on Gilbert's syndrome. J Med Genet 1975; 12: 152-156 [PMID: 1142378]
84. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, Lindhout D, Tytgat GN, Jansen PL, Oude Elferink RP. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 1995; 333: 1171-1175 [PMID: 7565971 DOI: 10.1056/NEJM199511023331802]
85. Hsieh TY, Shiu TY, Huang SM, Lin HH, Lee TC, Chen PJ, Chu HC, Chang WK, Jeng KS, Lai MM, Chao YC. Molecular pathogenesis of Gilbert's syndrome: decreased TATAbinding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet Genomics 2007; 17: 229-236 [PMID: 17496722 DOI: 10.1097/FPC.0b013e328012d0da]
86. Burchell B, Hume R. Molecular genetic basis of Gilbert's syndrome. J Gastroenterol Hepatol 1999; 14: 960-966 [PMID: 10530490 DOI: 10.1046/j.1440-1746.1999.01984.x]
87. Beutler E, Gelbart T, Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 1998; 95: 8170-8174 [PMID: 9653159]
88. Ki CS, Lee KA, Lee SY, Kim HJ, Cho SS, Park JH, Cho S, Sohn KM, Kim JW. Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin Chem 2003; 49: 2078-2081 [PMID: 14633881 DOI: 10.1373/clinchem.2003.024174]
89. Ando Y, Chida M, Nakayama K, Saka H, Kamataki T. The UGT1A1*28 allele is relatively rare in a Japanese population. Pharmacogenetics 1998; 8: 357-360 [PMID: 9731723]
90. Takeuchi K, Kobayashi Y, Tamaki S, Ishihara T, Maruo Y, Araki J, Mifuji R, Itani T, Kuroda M, Sato H, Kaito M, Adachi Y. Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J Gastroenterol Hepatol 2004; 19: 1023-1028 [PMID: 15304120 DOI: 10.1111/ j.1440-1746.2004.03370.x]
91. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, Miners JO. Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDPglucuronosyltransferase 1A substrates. Pharmacogenet Genomics 2007; 17: 1017-1029 [PMID: 18004206 DOI: 10.1097/ FPC.0b013e328256b1b6]
92. Kadakol A, Ghosh SS, Sappal BS, Sharma G, Chowdhury JR, Chowdhury NR. Genetic lesions of bilirubin uridinediphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat 2000; 16: 297-306 [PMID: 11013440]
93. Monaghan G, McLellan A, McGeehan A, Li Volti S, Mollica F, Salemi I, Din Z, Cassidy A, Hume R, Burchell B. Gilbert' s syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn. J Pediatr 1999; 134: 441-446 [PMID: 10190918]
94. Maruo Y, Nishizawa K, Sato H, Sawa H, Shimada M. Prolonged unconjugated hyperbilirubinemia associated with breast milk and mutations of the bilirubin uridine diphosphate-glucuronosyltransferase gene. Pediatrics 2000; 106: E59 [PMID: 11061796]
95. Burchell B, Soars M, Monaghan G, Cassidy A, Smith D, Ethell B. Drug-mediated toxicity caused by genetic deficiency of UDP-glucuronosyltransferases. Toxicol Lett 2000; 112-113: 333-340 [PMID: 10720749 DOI: 10.1016/S0378-4274(99)00209-X]
96. Maruo Y, Iwai M, Mori A, Sato H, Takeuchi Y. Polymorphism of UDP-glucuronosyltransferase and drug metabolism. Curr Drug Metab 2005; 6: 91-99 [PMID: 15853761 DOI: 10.2174/1389200053586064]
97. Rotger M, Taffe P, Bleiber G, Gunthard HF, Furrer H, Vernazza P, Drechsler H, Bernasconi E, Rickenbach M, Telenti A. Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J Infect Dis 2005; 192: 1381-1386 [PMID: 16170755 DOI: 10.1086/466531]
98. Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 2001; 98: 12671-12676 [PMID: 11606755 DOI: 10.1073/pnas.231140698]
99. Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab Dispos 2005; 33: 1729-1739 [PMID: 16118329 DOI: 10.1124/dmd.105.005447]
100. Ando Y, Saka H, Asai G, Sugiura S, Shimokata K, Kamataki T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann Oncol 1998; 9: 845-847 [PMID: 9789606]
101. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, Ratain MJ. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2002; 2: 43-47 [PMID: 11990381 DOI: 10.1038/sj.tpj.6500072]
102. Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics 2008; 9: 703-715 [PMID: 18518849 DOI: 10.2217/14622416.9.6.703]
103. Dubin IN, Johnson FB. Chronic idiopathic jaundice with unidentified pigment in liver cells; a new clinicopathologic entity with a report of 12 cases. Medicine (Baltimore) 1954; 33: 155-197 [PMID: 13193360]
104. Sprinz H, Nelson RS. Persistent non-hemolytic hyperbilirubinemia associated with lipochrome-like pigment in liver cells: report of four cases. Ann Intern Med 1954; 41: 952-962 [PMID: 13208040]
105. Shani M, Seligsohn U, Gilon E, Sheba C, Adam A. Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases. Q J Med 1970; 39: 549-567 [PMID: 5532959]
106. Erlinger S, Dhumeaux D, Desjeux JF, Benhamou JP. Hepatic handling of unconjugated dyes in the Dubin-Johnson syndrome. Gastroenterology 1973; 64: 106-110 [PMID: 4683844]
107. Swartz HM, Chen K, Roth JA. Further evidence that the pigment in the Dubin-Johnson syndrome is not melanin. Pigment Cell Res 1987; 1: 69-75 [PMID: 2853343 DOI: 10.1111/ j.1600-0749.1987.tb00392.x]
108. Hunter FM, Sparks RD, Flinner RL. Hepatitis with resulting mobilization of hepatic pigment in a patient with dubinjohnson syndrome. Gastroenterology 1964; 47: 631-635 [PMID: 14234683]
109. Watanabe S, Nishioka M, Kodama T, Ando K, Numa Y, Fukumoto Y, Okita K, Takemoto T, Mizuta M. Clinicopathological studies of the Dubin-Johnson syndrome complicated with chronic hepatitis. Gastroenterol Jpn 1982; 17: 576-584 [PMID: 7160601 DOI: 10.1007/BF02779135]
110. Kartenbeck J, Leuschner U, Mayer R, Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. Hepatology 1996; 23: 1061-1066 [PMID: 8621134 DOI: 10.1053/jhep.1996.v23.pm0008621134]
111. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP. Congenital jaundice in rats with a mutation in a multidrug resistanceassociated protein gene. Science 1996; 271: 1126-1128 [PMID: 8599091 DOI: 10.1126/science.271.5252.1126]
112. Paulusma CC, Kool M, Bosma PJ, Scheffer GL, ter Borg F, Scheper RJ, Tytgat GN, Borst P, Baas F, Oude Elferink RP. A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndrome. Hepatology 1997; 25: 1539-1542 [PMID: 9185779]
113. Wada M, Toh S, Taniguchi K, Nakamura T, Uchiumi T, Kohno K, Yoshida I, Kimura A, Sakisaka S, Adachi Y, Kuwano M. Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998; 7: 203-207 [PMID: 9425227 DOI: 10.1093/hmg/7.2.203]
114. Toh S, Wada M, Uchiumi T, Inokuchi A, Makino Y, Horie Y, Adachi Y, Sakisaka S, Kuwano M. Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am J Hum Genet 1999; 64: 739-746 [PMID: 10053008 DOI: 10.1086/302292]
115. Uchiumi T, Hinoshita E, Haga S, Nakamura T, Tanaka T, Toh S, Furukawa M, Kawabe T, Wada M, Kagotani K, Okumura K, Kohno K, Akiyama S, Kuwano M. Isolation of a novel human canalicular multispecific organic anion transporter, cMOAT2/MRP3, and its expression in cisplatinresistant cancer cells with decreased ATP-dependent drug transport. Biochem Biophys Res Commun 1998; 252: 103-110 [PMID: 9813153 DOI: 10.1006/bbrc.1998.9546]
116. Hulot JS, Villard E, Maguy A, Morel V, Mir L, Tostivint I, William-Faltaos D, Fernandez C, Hatem S, Deray G, Komajda M, Leblond V, Lechat P. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 2005; 15: 277-285 [PMID: 15864128]
117. Ahmed S, Vo NT, Thalhammer T, Thalhammer F, Gattringer KB, Jäger W. Involvement of Mrp2 (Abcc2) in biliary excretion of moxifloxacin and its metabolites in the isolated perfused rat liver. J Pharm Pharmacol 2008; 60: 55-62 [PMID: 18088505 DOI: 10.1211/jpp.60.1.0007]
118. Pedersen JM, Matsson P, Bergström CA, Norinder U, Hoogstraate J, Artursson P. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). J Med Chem 2008; 51: 3275-3287 [PMID: 18457386 DOI: 10.1021/jm7015683]
119. Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition. Expert Opin Drug Metab Toxicol 2006; 2: 351-366 [PMID: 16863439 DOI: 10.1517/17425255.2.3.351]
120. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981-2039 [PMID: 18691054 DOI: 10.2174/092986708785132870]
121. Cebecauerova D, Jirasek T, Budisova L, Mandys V, Volf V, Novotna Z, Subhanova I, Hrebicek M, Elleder M, Jirsa M. Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 2005; 129: 315-320 [PMID: 16012956 DOI: 10.1053/j.gastro.2004.10.009]
122. Rotor B, Manahan L, Florentin A. Familial non-hemolytic jaundice with direct van den Bergh reaction. Acta medica Philippina 1948; 5: 37-49
123. Wolkoff AW, Wolpert E, Pascasio FN, Arias IM. Rotor's syndrome. A distinct inheritable pathophysiologic entity. Am J Med 1976; 60: 173-179 [PMID: 766621 DOI: 10.1016/0002-934 3(76)90426-5]
124. Wolpert E, Pascasio FM, Wolkoff AW, Arias IM. Abnormal sulfobromophthalein metabolism in Rotor's syndrome and obligate heterozygotes. N Engl J Med 1977; 296: 1099-1101 [PMID: 850521 DOI: 10.1056/NEJM197705122961907]
125. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hřebíček M, Wagenaar E, van Esch A, de Waart DR, Oude Elferink RP, Kenworthy KE, Sticová E, al-Edreesi M, Knisely AS, Kmoch S, Jirsa M, Schinkel AH. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122: 519-528 [PMID: 22232210 DOI: 10.1172/ JCI59526]
126. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705 [PMID: 19785645 DOI: 10.1111/j.1476-5381.2009.00430.x]
127. Kalliokoski A, Neuvonen M, Neuvonen PJ, Niemi M. The effect of SLCO1B1 polymorphism on repaglinide pharmacokinetics persists over a wide dose range. Br J Clin Pharmacol 2008; 66: 818-825 [PMID: 18823304 DOI: 10.1111/ j.1365-2125.2008.03287.x]
128. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev 2011; 63: 157-181 [PMID: 21245207 DOI: 10.1124/pr.110.002857]
129. Iusuf D, Sparidans RW, van Esch A, Hobbs M, Kenworthy KE, van de Steeg E, Wagenaar E, Beijnen JH, Schinkel AH. Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice. Mol Pharm 2012; 9: 2497-2504 [PMID: 22812517 DOI: 10.1021/mp300108c]
130. Trauner M, Fickert P, Stauber RE. [New molecular aspects of cholestatic liver diseases]. Z Gastroenterol 1999; 37: 639-647 [PMID: 10458013]
131. Wagner M, Trauner M. Transcriptional regulation of hepatobiliary transport systems in health and disease: implications for a rationale approach to the treatment of intrahepatic cholestasis. Ann Hepatol 2005; 4: 77-99 [PMID: 16010241]
132. Kojima H, Nies AT, König J, Hagmann W, Spring H, Uemura M, Fukui H, Keppler D. Changes in the expression and localization of hepatocellular transporters and radixin in primary biliary cirrhosis. J Hepatol 2003; 39: 693-702 [PMID: 14568249 DOI: 10.1016/S0168-8278(03)00410-0]
133. Zollner G, Fickert P, Silbert D, Fuchsbichler A, Marschall HU, Zatloukal K, Denk H, Trauner M. Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. J Hepatol 2003; 38: 717-727 [PMID: 12763363 DOI: 10.1016/S0168-8278(03)00096-5]
134. Pauli-Magnus C, Kerb R, Fattinger K, Lang T, Anwald B, Kullak-Ublick GA, Beuers U, Meier PJ. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 2004; 39: 779-791 [PMID: 14999697 DOI: 10.1002/hep.20159]
135. Takeyama Y, Sakisaka S. Hepatobiliary membrane transporters in primary biliary cirrhosis. Hepatol Res 2012; 42: 120-130 [PMID: 22175826 DOI: 10.1111/j.1872-034X.2011.00912.x]
136. Chen HL, Liu YJ, Chen HL, Wu SH, Ni YH, Ho MC, Lai HS, Hsu WM, Hsu HY, Tseng HC, Jeng YM, Chang MH. Expression of hepatocyte transporters and nuclear receptors in children with early and late-stage biliary atresia. Pediatr Res 2008; 63: 667-673 [PMID: 18327154 DOI: 10.1203/ PDR.0b013e318170a6b5]
137. Oswald M, Kullak-Ublick GA, Paumgartner G, Beuers U. Expression of hepatic transporters OATP-C and MRP2 in primary sclerosing cholangitis. Liver 2001; 21: 247-253 [PMID: 11454187 DOI: 10.1034/j.1600-0676.2001.021004247.x]
138. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106: 97-132 [PMID: 15781124]
139. Roth M, Obaidat A, Hagenbuch B. OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol 2012; 165: 1260-1287 [PMID: 22013971 DOI: 10.1111/j.1476-5381.2011.01724.x]
140. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P. Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem 2012; 55: 4740-4763 [PMID: 22541068 DOI: 10.1021/jm300212s]
141. Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet 2011; 26: 220-227 [PMID: 21297316 DOI: 10.2133/dmpk]
142. Sissung TM, Baum CE, Kirkland CT, Gao R, Gardner ER, Figg WD. Pharmacogenetics of membrane transporters: an update on current approaches. Mol Biotechnol 2010; 44: 152-167 [PMID: 19950006 DOI: 10.1007/s12033-009-9220-6]
143. Sadée W, Dai Z. Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 2005; 14 Spec No. 2: R207-R214 [PMID: 16244319]